NxStage Medical Inc. (NASDAQ:NXTM) Director Craig W. Moore sold 3,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $23.31, for a total value of $69,930.00. Following the completion of the transaction, the director now directly owns 90,739 shares in the company, valued at $2,115,126.09. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

NxStage Medical Inc. (NASDAQ:NXTM) opened at 23.95 on Tuesday. The firm’s market cap is $1.55 billion. The firm has a 50-day moving average price of $23.62 and a 200-day moving average price of $19.53. NxStage Medical Inc. has a 1-year low of $13.49 and a 1-year high of $26.07.

NxStage Medical (NASDAQ:NXTM) last released its quarterly earnings data on Thursday, August 4th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.01. NxStage Medical had a negative return on equity of 3.79% and a negative net margin of 2.06%. The company earned $92.20 million during the quarter, compared to analysts’ expectations of $89.44 million. During the same period last year, the firm posted ($0.08) earnings per share. The business’s revenue was up 14.8% on a year-over-year basis. On average, analysts expect that NxStage Medical Inc. will post ($0.12) earnings per share for the current fiscal year.

Several research analysts have commented on NXTM shares. Zacks Investment Research downgraded NxStage Medical from a “buy” rating to a “hold” rating in a research report on Wednesday, August 10th. BTIG Research reaffirmed a “buy” rating and issued a $29.00 price target on shares of NxStage Medical in a research report on Sunday, August 7th. Jefferies Group lifted their price target on NxStage Medical from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Friday, August 5th. Northland Securities set a $25.00 price target on NxStage Medical and gave the stock a “buy” rating in a research report on Thursday, September 15th. Finally, Canaccord Genuity lifted their price target on NxStage Medical from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, August 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. NxStage Medical presently has a consensus rating of “Buy” and a consensus price target of $26.43.

Several hedge funds have recently added to or reduced their stakes in the stock. Acrospire Investment Management LLC boosted its stake in NxStage Medical by 1,459.3% in the second quarter. Acrospire Investment Management LLC now owns 4,678 shares of the medical device company’s stock worth $101,000 after buying an additional 4,378 shares during the last quarter. Pacad Investment Ltd. purchased a new position in shares of NxStage Medical during the second quarter worth $111,000. BNP Paribas Arbitrage SA raised its position in shares of NxStage Medical by 57.5% in the second quarter. BNP Paribas Arbitrage SA now owns 5,548 shares of the medical device company’s stock worth $120,000 after buying an additional 2,026 shares during the period. BlackRock Inc. raised its position in shares of NxStage Medical by 50.6% in the second quarter. BlackRock Inc. now owns 6,299 shares of the medical device company’s stock worth $136,000 after buying an additional 2,116 shares during the period. Finally, Cutler Group LP raised its position in shares of NxStage Medical by 28.3% in the second quarter. Cutler Group LP now owns 7,168 shares of the medical device company’s stock worth $155,000 after buying an additional 1,583 shares during the period. 98.26% of the stock is owned by institutional investors.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical device company. The Company is engaged in the development, manufacturing and marketing of products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s products include the System One, Streamline Blood Tubing Sets and AV Fistula and Apheresis Needles.

5 Day Chart for NASDAQ:NXTM

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.